CAR-T cell therapy re-engineers a patient’s own immune cells to hunt glioblastoma directly. Doctors collect T cells, modify them genetically, then infuse them back into the patient.
This guide explains how the process works, what trial results show so far, and which risks patients should understand. It also covers current FDA approval status for this evolving treatment.
What Is CAR-T Cell Therapy?
CAR-T stands for chimeric antigen receptor T-cell therapy. Essentially, scientists add a synthetic receptor to a patient’s T cells. This receptor helps the T cells recognize a specific marker on tumor cells.
Consequently, the modified cells can find and attack cancer cells that they would otherwise ignore. Doctors first proved this approach against blood cancers like leukemia before adapting it for solid tumors.
How Doctors Engineer CAR-T Cells
Creating CAR-T cells requires several precise laboratory steps. Each step takes time, so the full process usually spans a few weeks.
- Doctors collect white blood cells from the patient through a process called leukapheresis.
- Scientists isolate T cells and insert a gene for the chimeric antigen receptor.
- The lab expands these engineered cells into millions of copies.
- Doctors infuse the finished CAR-T cells back into the patient, sometimes after chemotherapy that clears space for them.
Afterward, the care team monitors the patient closely for both response and side effects.
CAR-T Targets in Glioblastoma
Researchers must choose a target marker that appears on tumor cells but not on healthy brain tissue. Several candidate markers now guide active trials.
| Target | Why Researchers Chose It |
|---|---|
| EGFRvIII | A mutated receptor found only on tumor cells in some glioblastomas |
| IL13Rα2 | Overexpressed on glioblastoma cells compared with normal brain tissue |
| HER2 | Present on a subset of glioblastoma tumors, also studied in breast cancer |
| B7-H3 | Broadly expressed across glioblastoma, now advancing to Phase II trials |
Notably, no single marker appears on every glioblastoma cell. Therefore, some trials now target two markers at once to reduce the chance that tumor cells escape detection.
Clinical Trial Results So Far
Early results show meaningful but inconsistent responses. For example, a Penn Medicine dual-target trial shrank tumors in nearly two-thirds of patients with recurrent glioblastoma. Several patients survived twelve months or longer, which stands out given typical survival for this group.
Similarly, case reports using IL13Rα2-targeted cells have shown temporary tumor regression. However, published Phase I data across thirteen studies covers only about 128 patients total. As a result, researchers still need larger trials before drawing firm conclusions.
FDA Approval Status
No CAR-T therapy currently holds FDA approval for glioblastoma or any brain tumor. Every option remains investigational and available only through clinical trials.
In late 2025, the FDA cleared an investigational new drug application for a B7-H3-targeted CAR-T therapy, allowing a Phase II trial in recurrent glioblastoma to proceed. This step moves the field forward, though it does not represent approval.
Who Might Qualify for a CAR-T Trial
Eligibility criteria vary by trial and target marker. Generally, though, several factors tend to matter most.
- Confirmed glioblastoma diagnosis, often recurrent after standard treatment
- Tumor tissue available for biomarker testing, such as EGFRvIII or IL13Rα2 status
- Adequate organ function and overall strength to tolerate the procedure
- No other active cancer or uncontrolled infection at enrollment
Consequently, a specialist must review pathology and imaging before confirming eligibility.
CAR-T Cells vs CAR-NK Cells
Researchers also engineer natural killer cells with the same chimeric antigen receptor technology. This approach, called CAR-NK therapy, may cause fewer inflammatory side effects than CAR-T therapy.
However, CAR-NK cells sometimes persist for a shorter time in the body. Our NK cell therapy for glioblastoma page explains this related approach and its own trial evidence.
CAR-T Compared With Other Immunotherapy Approaches
Patients often ask how CAR-T therapy compares with other options covered in our complete immunotherapy guide.
| Therapy | Approach | Development Stage |
|---|---|---|
| CAR-T cell therapy | Engineered T cells attack a chosen marker | Phase I and II trials |
| Checkpoint inhibitors | Drugs remove brakes on existing immune cells | Limited benefit shown alone |
| Dendritic cell vaccines | Trains immune cells using tumor proteins | Phase 3 data reported |
In contrast to checkpoint inhibitors, CAR-T therapy adds a completely new weapon rather than only unleashing existing ones. Our checkpoint inhibitor guide explains that approach in detail.
Recurrent vs Newly Diagnosed Glioblastoma Trials
Most current CAR-T trials enroll patients with recurrent glioblastoma, since this group has fewer standard options left. However, some newer trials now target newly diagnosed patients directly, hoping to intervene earlier.
| Trial Type | Typical Patient | Goal |
|---|---|---|
| Recurrent glioblastoma trial | Tumor returned after surgery, radiation, and chemotherapy | Extend survival, control regrowth |
| Newly diagnosed trial | Freshly diagnosed, often post-surgery | Delay or prevent recurrence entirely |
Consequently, the right trial type depends heavily on when a patient receives their diagnosis relative to prior treatment.
Challenges Facing CAR-T Therapy for Brain Tumors
Solid brain tumors present obstacles that blood cancers rarely do. First, glioblastoma cells vary widely even within one tumor, so a single target often misses many cells.
- Antigen heterogeneity: tumor cells lose the target marker over time.
- The blood-brain barrier limits how many CAR-T cells reach the tumor.
- The tumor microenvironment actively suppresses immune cell activity nearby.
- Manufacturing each patient’s personalized cell product takes weeks.
Therefore, researchers now test dual-target designs and local delivery methods to address these limits directly.
CAR-T Research Centers Around the World
Several academic centers now lead active glioblastoma CAR-T trials. For example, Penn Medicine, City of Hope, and Duke University all run distinct programs in the United States. Meanwhile, research groups in China and Europe study parallel approaches.
Consequently, patients seeking a trial should compare target markers, trial phase, and location together, since travel and monitoring requirements differ between programs.
Monitoring After CAR-T Infusion
Doctors schedule frequent follow-up scans after CAR-T infusion. Immune activity around the tumor can temporarily make it look larger on MRI, a pattern called pseudoprogression.
- Blood tests track inflammatory markers linked to cytokine release syndrome.
- Neurological exams check for early signs of ICANS.
- Follow-up MRI scans use specialized criteria to distinguish true progression from swelling.
Therefore, patients typically remain near the treatment center for close observation during the first few weeks.
Side Effects: Cytokine Release Syndrome and ICANS
CAR-T therapy can trigger cytokine release syndrome, a systemic inflammatory reaction. It can also cause a brain-specific reaction called ICANS, short for immune effector cell-associated neurotoxicity syndrome.
Fortunately, most reported neurotoxicity remains mild, and only a small share of patients develop severe grade 3 or higher events. Doctors typically manage these reactions with corticosteroids or the drug tocilizumab. Our immunotherapy side effects guide explains grading and management in full.
Combining CAR-T With Other Therapies
Researchers increasingly pair CAR-T cells with other immune strategies. For instance, adding a checkpoint inhibitor may prevent CAR-T cells from becoming exhausted inside the tumor.
Additionally, some centers now study oncolytic viruses that prime the tumor before CAR-T infusion. Our oncolytic virus therapy guide explains how this priming effect works.
What to Expect During CAR-T Treatment
Patients typically move through a defined sequence of steps once enrolled in a trial.
- Initial screening confirms tumor markers and overall eligibility.
- Doctors collect T cells through leukapheresis, usually an outpatient procedure.
- The manufacturing lab prepares the personalized CAR-T product over one to three weeks.
- Patients receive the infusion, often following a short course of conditioning chemotherapy.
- The care team monitors patients closely for one to two weeks afterward, watching for CRS or ICANS.
Consequently, most trials require patients to stay near the treatment center during this monitoring period.
Cost and Access Considerations
Trial sponsors typically cover the cost of the CAR-T product itself. However, patients often pay for travel, lodging, and any standard-of-care treatment given alongside the trial. Additionally, insurance rarely covers experimental cell therapy directly.
Consequently, international patients should request a full cost breakdown before enrolling anywhere. Our clinic helps coordinate this review for patients considering treatment in Istanbul through our contact page.
Getting a Second Opinion Before Starting Treatment
Any experimental treatment decision benefits from an independent second opinion. Specifically, a neuro-oncology specialist can confirm whether a patient’s tumor biology truly matches a given trial’s target.
Furthermore, a second opinion often clarifies whether standard treatment options remain available first. Our team reviews imaging and pathology for international patients through our contact page before recommending any next step.
Key Terms Explained
- Leukapheresis: A procedure that separates white blood cells from a blood sample.
- Antigen escape: When tumor cells stop expressing the marker a therapy targets.
- Lymphodepletion: Chemotherapy given before infusion to make room for new cells.
- Tumor microenvironment: The surrounding tissue and immune cells that influence tumor behavior.
Why Glioblastoma Trials Take Time to Show Results
Glioblastoma grows quickly, so researchers must track survival carefully over months, not weeks. Additionally, small early trials cannot yet prove a survival benefit with statistical confidence.
Therefore, patients should treat early positive reports as encouraging, not conclusive. Larger randomized trials remain necessary before any CAR-T product can seek approval.
Frequently Asked Questions
Is CAR-T cell therapy approved for glioblastoma?
No. CAR-T therapy remains investigational for glioblastoma and is available only through clinical trials as of 2026.
How long does CAR-T cell manufacturing take?
Manufacturing usually takes one to three weeks, since the lab must isolate, modify, and expand each patient’s own cells individually.
What is the biggest risk of CAR-T therapy for brain tumors?
Cytokine release syndrome and ICANS represent the most serious risks. However, specialized centers monitor patients closely and manage most cases successfully.
Can CAR-T therapy be combined with surgery?
Yes, several trials deliver CAR-T cells directly into the surgical cavity after tumor removal, aiming to reach residual cells more effectively.
Why does glioblastoma respond less consistently than leukemia to CAR-T therapy?
Glioblastoma cells vary more between patients and even within one tumor. Additionally, the blood-brain barrier limits how many cells reach the tumor site.
How can international patients access a CAR-T trial?
A specialist should first review pathology, imaging, and biomarker testing. Contact our clinic contact page to discuss trial referral options.
Does CAR-T therapy work better with a specific tumor marker?
Not universally. Response often depends on how strongly the tumor expresses the chosen target, so biomarker testing guides trial selection closely.
What happens if a glioblastoma tumor stops responding to CAR-T therapy?
Doctors then reassess the tumor and typically consider other trials, combination approaches, or standard treatment options. Therefore, ongoing monitoring remains essential throughout care.
How many CAR-T infusions does a glioblastoma patient usually receive?
Protocols vary widely. Some trials give a single infusion, while others deliver repeated doses directly into the surgical cavity over several weeks.
Can CAR-T therapy shrink a tumor permanently?
Sometimes tumors shrink substantially for months, though durable, long-term control still remains rare. Consequently, researchers continue refining targets and delivery methods to improve durability.
Reviewed by Prof. Dr. Serdar Baki Albayrak, Neurosurgeon, Istanbul, Turkey.
Medical Disclaimer: This article provides general information only and does not replace professional medical diagnosis or treatment. Please consult Prof. Dr. Serdar Baki Albayrak or another qualified physician directly to discuss your specific condition.
Request an Appointment
Do you have questions about your diagnosis or treatment options? Send your details below, and our team will contact you to schedule a consultation.
